IBR-7

IBR-7 is a **synthetic derivative of ibrutinib**, developed to enhance anti-cancer activity—particularly against solid tumors such as non-small cell lung cancer (NSCLC) and pancreatic cancer—relative to its parent compound. Unlike ibrutinib, which primarily inhibits Bruton's tyrosine kinase (BTK), IBR-7 exerts a dual mechanism of action by inhibiting both **epidermal growth factor receptor (EGFR)** and suppressing the **mammalian target of rapamycin complex 1 (mTORC1)/S6 signaling pathway**[1][3][5]. It has demonstrated **enhanced cytotoxicity** in EGFR wild-type NSCLC models and acts as a potent radiosensitizer and chemosensitizer in pancreatic cancer, improving the efficacy of agents such as radiation and gemcitabine[3][5]. IBR-7 induces G2/M cell cycle arrest, apoptosis via mitochondrial mechanisms, and can overcome resistance mechanisms linked to Mcl-1 expression[1][5]. Preclinical studies suggest potential superiority over ibrutinib for certain solid tumors, though clinical development status is early and limited to preclinical or investigational settings.

Other names

IBR-7IBR7IBR 7